GROWTH HORMONE AXIS RESEARCH / COMPARE
Four Routes to the Same Pituitary Cell
Sermorelin, ipamorelin, CJC-1295, and the CJC-1295/ipamorelin combination, compared on mechanism, evidence maturity, and what each was actually studied for.
The short version
All four compounds on this desk push the pituitary gland to release its own growth hormone, but they differ in which receptor they use, how long a single dose lasts, and how much controlled human evidence backs them up. Sermorelin has an FDA approval history and the deepest range of human trial doses; ipamorelin has the thinnest human evidence and a failed Phase 2 primary endpoint; CJC-1295 stretches the same GHRH mechanism across days; and the CJC-1295/ipamorelin combination has never been tested as a fixed blend at all. This page lines the four up so the differences are explicit rather than assumed.
Receptor and mechanism
Sermorelin and CJC-1295 both bind the GHRH receptor on pituitary somatotrophs, activating the cAMP/PKA pathway. Sermorelin is the unmodified GHRH(1-29) fragment; CJC-1295 carries four stability-conferring substitutions and, in its DAC form, a covalent albumin-binding linker. Ipamorelin instead binds GHS-R1a, the ghrelin receptor, through a Gq/calcium pathway — a mechanism distinct from the GHRH arm. The CJC-1295/ipamorelin combination activates both receptors on the same cell, which co-activation studies in transfected cells suggest can roughly double the cAMP response versus GHRH-receptor activation alone [20].
Duration of a single dose
This is where the four differ most. Ipamorelin produces a single, short GH pulse — human pharmacokinetic modeling puts its terminal half-life at about 2 hours, with the GH response peaking roughly 40 minutes after dosing [11]. Sermorelin's own IV pharmacokinetic data show GH elevated for about 3 hours despite rapid plasma clearance [6]. CJC-1295 without DAC behaves similarly to sermorelin in duration. CJC-1295 with DAC is the outlier: a single dose raised GH for 6 or more days and IGF-1 for 9 to 11 days in one trial, with an estimated half-life of 5.8 to 8.1 days [15].
Regulatory and evidence status
| Compound | FDA history | Human trial evidence |
|---|---|---|
| Sermorelin | Previously approved (Geref, NDA 020443); withdrawn 2008 for commercial reasons | Multiple controlled human trials across decades, including pediatric growth and older-adult dosing studies [2][5][6][7] |
| Ipamorelin | Never approved; removed from interim 503A Category 2 in 2024 after nominator withdrawal; reviewed at the Oct. 2024 PCAC meeting | One Phase 2 RCT (missed primary endpoint) plus a single-dose human PK/PD study [10][11] |
| CJC-1295 | Never approved; flagged for immunogenicity concerns in 2024 PCAC briefing materials | Small pharmacology studies in healthy adults; no Phase 3 program [14][15][16] |
| CJC-1295/Ipamorelin | Neither component approved | No trial of the fixed combination; evidence is inferred from each component plus receptor cross-talk data [20] |
Only sermorelin carries a genuine approval history. The other three sit entirely in research-chemical territory, and the combination has the thinnest direct evidence of all, because it has never itself been the subject of a trial.
What each is studied for
Sermorelin's trial record centers on pediatric growth hormone deficiency and reversing age-related declines in GH and IGF-1 in older adults [5][7]. Ipamorelin's strongest human data point is a postoperative-ileus trial that did not show a significant benefit [10], alongside preclinical work on chemotherapy-associated weight loss [8] and bone growth in rats [12]. CJC-1295's studies focus narrowly on GH/IGF-1 pharmacodynamics and pulsatility preservation in healthy adults [15][16]. The combination has no dedicated trials; the closest supporting data is a 2026 meta-analysis of the related GHRH analog tesamorelin, showing body-composition benefit with a favorable short-term safety profile [17], and a class-wide secretagogue safety review [18].